Difference between revisions of "Dabigatran (Pradaxa)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Competitive direct thrombin inhibitor. Inhibition of thrombin, a serine protease, inhibits the conversion of fibrinogen into fibrin in the coagulation cascade and subsequent development of thrombus. Dabigatran inhibits free thrombin, clot-bound thrombin, and thrombin-induced platelet aggregation.<ref name="insert">[ | + | Class/mechanism: Competitive direct thrombin inhibitor. Inhibition of thrombin, a serine protease, inhibits the conversion of fibrinogen into fibrin in the coagulation cascade and subsequent development of thrombus. Dabigatran inhibits free thrombin, clot-bound thrombin, and thrombin-induced platelet aggregation.<ref name="insert">[https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf Dabigatran (Pradaxa) package insert]</ref><ref>[[Media:Dabigatran.pdf | Dabigatran (Pradaxa) package insert (locally hosted backup)]]</ref><ref>[http://www.pradaxa.com Pradaxa manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 10: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf Dabigatran (Pradaxa) package insert]<ref name="insert"></ref> |
*[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]</ref> | ||
Revision as of 13:59, 16 September 2018
General information
Class/mechanism: Competitive direct thrombin inhibitor. Inhibition of thrombin, a serine protease, inhibits the conversion of fibrinogen into fibrin in the coagulation cascade and subsequent development of thrombus. Dabigatran inhibits free thrombin, clot-bound thrombin, and thrombin-induced platelet aggregation.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Reversal information
Idarucizumab (Praxbind) can rapidly and completely reverse the effects of dabigatran as measured by normalization of dilute thrombin time.
Patient drug information
Also known as
- Brand names: Pradax, Pradaxa, Prazaxa